Please wait while the formulary information is being retrieved.
VITAMIN K1 (PHYTONADIONE (VIT K1))
- Hypoprothrombinemia
- Antibiotic-induced hypoprothrombinemia
- Anticoagulant-induced prothrombin deficiency
- Hemorrhagic disease of newborn due to vitamin K def
- Prevention of hemorrhagic disease of newborn
- Vitamin K deficiency induced hypoprothrombinemia
- Vitamin K1 Injection Solution
- Vitamin K Injection Solution
- Phytonadione (vitamin K1) Injection Solution
- By Indication
10 mg/mL injection solution
- Inject 1 milliliter (10 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
vitamin K 1 mg/0.5 mL injection solution
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
1 mg/0.5 mL injection solution
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
10 mg/mL injection solution
- Inject 1 milliliter (10 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
Antibiotic-induced hypoprothrombinemia
- Inject 0.5 milliliter (5 mg) by intramuscular route once
- Inject 0.5 milliliter (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2.5 milliliters (5 mg) by intramuscular route once
- Inject 2.5 milliliters (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Infuse 5 milliliters (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 5 milliliters (10 mg) by intramuscular route once
- Inject 1 milliliter (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1 milliliter (10 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 0.25 milliliter (2.5 mg) by intramuscular route once
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route once
- Inject 1.25 milliliters (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1.25 milliliters (2.5 mg) by intramuscular route once
- Inject 0.25 milliliter (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
Anticoagulant-induced prothrombin deficiency
- Inject 0.5 milliliter (5 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 0.5 milliliter (5 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 0.5 milliliter (5 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 2.5 milliliters (5 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 2.5 milliliters (5 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Infuse 5 milliliters (10 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 5 milliliters (10 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 1 milliliter (10 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 1 milliliter (10 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 1 milliliter (10 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 1.5 milliliters (15 mg) by intramuscular route x1 dose; may berepeated in 6 to 8 hours after the first dose
- Inject 1.5 milliliters (15 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Infuse 1.5 milliliters (15 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Infuse 2 milliliters (20 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 2 milliliters (20 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 2 milliliters (20 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 2.5 milliliters (25 mg) by intramuscular route x1 dose; may berepeated in 6 to 8 hours after the first dose
- Infuse 2.5 milliliters (25 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 1.25 milliliters (2.5 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route x1 dose; may be repeated in 6 to 8 hours after the first dose
- Inject 1.25 milliliters (2.5 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hoursafter the first dose
- Inject 0.25 milliliter (2.5 mg) by subcutaneous route x1 dose; may berepeated in 6 to 8 hours after the first dose
- Inject 0.25 milliliter (2.5 mg) by intravenous route once, by slow injection not exceeding 1Mg per minute; may be repeated in 6 to 8 hours after the first dose
- Inject 0.25 milliliter (2.5 mg) by intramuscular route x1 dose; may be repeated in 6 to 8 hours after the first dose
Hypoprothrombinemia
- Inject 0.5 milliliter (5 mg) by intramuscular route once
- Inject 0.5 milliliter (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2.5 milliliters (5 mg) by intramuscular route once
- Inject 2.5 milliliters (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Infuse 5 milliliters (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 5 milliliters (10 mg) by intramuscular route once
- Inject 1 milliliter (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1 milliliter (10 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 0.25 milliliter (2.5 mg) by intramuscular route once
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route once
- Inject 1.25 milliliters (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1.25 milliliters (2.5 mg) by intramuscular route once
- Inject 0.25 milliliter (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
Vitamin K deficiency induced hypoprothrombinemia
- Inject 0.5 milliliter (5 mg) by intramuscular route once
- Inject 0.5 milliliter (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2.5 milliliters (5 mg) by intramuscular route once
- Inject 2.5 milliliters (5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Infuse 5 milliliters (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 5 milliliters (10 mg) by intramuscular route once
- Inject 1 milliliter (10 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1 milliliter (10 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intramuscular route once
- Inject 1.5 milliliters (15 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 2 milliliters (20 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intramuscular route once
- Inject 2.5 milliliters (25 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 0.25 milliliter (2.5 mg) by intramuscular route once
- Inject 1.25 milliliters (2.5 mg) by subcutaneous route once
- Inject 1.25 milliliters (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- Inject 1.25 milliliters (2.5 mg) by intramuscular route once
- Inject 0.25 milliliter (2.5 mg) by intravenous route once, by slow injection not exceeding 1 mg per minute
- None
Contraindicated
- Coumadin
- Jantoven
- warfarin
Severe
Moderate
- None
- Hemolytic anemia from PK and g6PD deficiencies
Contraindicated
- None
Severe
Moderate
- None
VITAMIN K1 (PHYTONADIONE (VIT K1))
- Hypoprothrombinemia
- Antibiotic-induced hypoprothrombinemia
- Anticoagulant-induced prothrombin deficiency
- Hemorrhagic disease of newborn due to vitamin K def
- Prevention of hemorrhagic disease of newborn
- Vitamin K deficiency induced hypoprothrombinemia
- None
- None
More Frequent
Severe
Less Severe
- None
- Dysgeusia
- Flushing
- Injection site sequelae
- Skin swelling
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Cyanosis
- Dizziness
- Hyperbilirubinemia
- Hyperhidrosis
- Hypersensitivity drug reaction
- Hypotension
- Skin lesion
Less Severe
- Dyspnea
- Eczema
- Erythema
- Erythema dyschromicum perstans
- Pseudoscleroderma
- Tachycardia
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Phytonadione (vit K-1)
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Phytonadione
None
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- The injectable form of vitamin K can rarely cause severe (sometimes fatal) allergic reactions when given by injection into a muscle or vein. Therefore, vitamin K should be injected into a muscle or vein only when it cannot be given by injection under the skin or taken by mouth, or when your doctor has judged that the benefit is greater than the risk. Seek immediate medical attention if you experience symptoms of an allergic reaction such as rash, itching, swelling, dizziness, or trouble breathing.
| Antibiotic-induced hypoprothrombinemia | |
| D68.4 | Acquired coagulation factor deficiency |
| Anticoagulant-induced prothrombin deficiency | |
| D68.4 | Acquired coagulation factor deficiency |
| Hemorrhagic disease of newborn due to vitamin K def | |
| P53 | Hemorrhagic disease of newborn |
| Hypoprothrombinemia | |
| D68.4 | Acquired coagulation factor deficiency |
| Vitamin K deficiency induced hypoprothrombinemia | |
| D68.4 | Acquired coagulation factor deficiency |
| 0-9 | A-Z |
|---|---|
| D68.4 | Acquired coagulation factor deficiency |
| D68.4 | Acquired coagulation factor deficiency |
| D68.4 | Acquired coagulation factor deficiency |
| D68.4 | Acquired coagulation factor deficiency |
| P53 | Hemorrhagic disease of newborn |
Formulary Reference Tool